XTL6001再获EASD 2026两项口头报告：三靶点协同引领糖尿病与代谢疾病治疗新方向
MICOT
点击蓝字 关注我们
Slide to view different languages
滑动查看不同语言
2026年9月28日至10月2日，第62届欧洲糖尿病研究协会（EASD）年会将在意大利米兰召开。麦科奥特自主研发的全球首创三靶点长效蛋白药物XTL6001，其在减重与慢性肾病（CKD）/糖尿病肾病（DKD）两大领域的研究成果成功入选本届大会，并均获选为口头报告（Oral Presentation）。
在EASD的摘要评审体系中，口头报告（Oral）由科学计划委员会（Scientific Programme Committee）在全部匿名评审通过的摘要中择优指派，代表大会对研究创新性、数据完整性与临床相关性的最高优先级认定。
心-肾-代谢综合管理，与EASD主题高度契合
本次EASD年会以 “Discover what‘s next in diabetes science and care” （探索糖尿病科学与照护的未来）为核心愿景。在当前国际糖尿病与代谢疾病领域，诊疗理念正从单纯的“控糖”向“心-肾-代谢综合管理”深度转变。多个国际指南均强调，糖尿病管理需同时关注肥胖、心血管风险与慢性肾病的协同治疗。
XTL6001正是这一前沿理念的完美实践者。作为全球首个且唯一进入临床阶段的GLP-1R/GCGR/MasR三靶点激动剂，其作用机制与EASD 2026所倡导的多维度、跨学科治疗趋势高度契合——不仅关注血糖与体重，更直接作用于肾脏保护与代谢改善，为“心-肾-代谢”综合征的“一药多效”治疗提供了全新的解决方案。
“减脂保肌”优势显著：
当前以GLP-1类药物为代表的减重疗法虽效果显著，但普遍面临肌肉流失、胃肠道不耐受等挑战。XTL6001创新地引入MasR靶点，在临床前研究中展现出颠覆性优势：
01
“减脂保肌”的突破性疗效：MasR靶点可主动阻断骨骼肌蛋白质降解通路，在实现显著减重的同时有效保护肌肉，从机制层面破解了现有减重药物"减脂必减肌"的困局。
02
卓越的耐受性与安全性：三靶点协同作用可在不显著抑制食欲的情况下实现减重，提示相比传统GLP-1药物，其胃肠道不良事件风险更低，有望成为长期体重管理的更优选择。
03
多器官保护潜力：除减重外，研究还展示了其在降低尿酸、改善肝肾功能方面的潜力，契合CKD/DKD治疗的巨大未满足需求。
此前，XTL6001已在中美两国获批开展临床试验，并在中国顺利完成I期临床。继ADA科学年会之后，此次减重与CKD/DKD两项研究成果双双入选EASD口头报告，标志着其独特的MasR/GCGR/GLP-1R三靶点协同机制获得了全球顶尖学术平台的高度认可，在全球竞争激烈的GLP-1/多靶点药物研发版图中已占据一席之地。
我们诚挚邀请全球糖尿病与代谢领域的专家、学者及合作伙伴，相聚意大利米兰，共同见证XTL6001的最新研究成果发布。
会议名称：第62届EASD年会
时间：2026年9月28日 - 10月2日
地点：意大利·米兰（Allianz MiCo）
形式：口头报告 （Oral Presentation）
麦科奥特期待在米兰与您探讨代谢疾病治疗的未来！
MICOT
The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) will be held in Milan, Italy, from September 28 to October 2, 2026. XTL6001, Micot’s independently developed, long-acting triple-target protein therapeutic, has had research findings in two major areas—weight loss and chronic kidney disease (CKD)/diabetic kidney disease (DKD)—accepted for this year’s congress, with both selected as Oral Presentations.
Under EASD’s abstract review system, Oral Presentations are assigned by the Scientific Programme Committee from among all abstracts that pass blinded review. This reflects the congress’s highest-priority recognition of a study’s innovation, data completeness, and clinical relevance.
Cardio-Renal-Metabolic Integrated Management, Highly Aligned with the EASD Theme
The core vision of this year’s EASD Annual Meeting is “Discover what’s next in diabetes science and care.” Across the global diabetes and metabolic disease field, the treatment paradigm is shifting from glycemic control alone toward integrated cardio-renal-metabolic management. Multiple international guidelines emphasize that diabetes management should address obesity, cardiovascular risk, and chronic kidney disease in a coordinated manner.
XTL6001 embodies this frontier concept. As the world’s first and only GLP-1R/GCGR/MasR triple agonist to enter clinical development, its mechanism of action is highly aligned with the multidimensional, interdisciplinary treatment trend advocated by EASD 2026. Beyond blood glucose and body weight, XTL6001 directly addresses renal protection and metabolic improvement, offering a new single-therapy solution with multiple benefits for cardio-renal-metabolic syndrome.
Fat Loss with Muscle Preservation：
While weight-loss therapies represented by GLP-1 agonists deliver remarkable efficacy, they commonly face challenges such as muscle loss and gastrointestinal intolerance. By innovatively incorporating the MasR, XTL6001 has demonstrated disruptive advantages in preclinical studies:
01
Fat Reduction with Muscle Preservation: MasR actively blocks the skeletal muscle protein degradation pathway, enabling substantial weight loss while effectively preserving muscle mass. This mechanistically resolves the inherent dilemma of current weight-loss medications—“fat loss is inevitably accompanied by muscle loss”.
02
Excellent tolerability and safety: The synergistic action of the three targets can achieve weight loss without marked appetite suppression, suggesting a lower risk of gastrointestinal adverse events versus conventional GLP-1 therapies. XTL6001 therefore has the potential to become an improved option for long-term weight management.
03
Potential for multi-organ protection: Beyond weight loss, studies have also shown its potential to lower serum uric acid levels and improve hepatic and renal function, aligning with the substantial unmet need in CKD/DKD treatment.
Previously, XTL6001 had received approval to conduct clinical trials in China and the United States, and successfully completed its Phase 1 clinical trial in China. Following the ADA Scientific Sessions, the acceptance of both its weight loss and CKD/DKD studies as Oral Presentations at EASD marks strong recognition from a leading global academic congress of its unique MasR/GCGR/GLP-1R triple-target synergistic mechanism. It also demonstrates that XTL6001 has established a differentiated position in the highly competitive global GLP-1/multi-target drug development landscape.
We sincerely invite experts, researchers, and partners across the global diabetes and metabolic disease field to join us in Milan, Italy, for the presentation of the latest research findings on XTL6001.
Congress: 62nd Annual Meeting of the European Association for the Study of Diabetes
Date: September 28 – October 2, 2026
Venue: Allianz MiCo, Milan, Italy
Format: Oral Presentation
Micot looks forward to discussing the future of metabolic disease therapy with you in Milan.
MICOT
详情
奋斗为本、求是创新、协作共赢
